Results 151 to 160 of about 2,304,873 (264)

HDAC inhibitors reverse YAP-driven immune resistance in NSCLC: mechanistic and translational evidence. [PDF]

J Immunother Cancer
Zhang X, Huang L, Li J, Cai Y, Chen W, Ren Y, Yuan X, Sun W, Sun S, Chu Q.   +9 more
europepmc   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Enhancing Shape Sensing of Slender Medical Continuum Robot Using Carbon Nanotube Piezoresistive Fiber Bandage. [PDF]

Cyborg Bionic Syst
Xiang P, Mi X, Zhang H, Wang F, Yang X, Wang Y, Xiong R, Liu S, Lu H.   +8 more
europepmc   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

<i>PARP9</i> Modulates Sunitinib Resistance in Clear Cell Renal Cell Carcinoma via <i>STAT1</i>/<i>IRF1</i> Signaling Pathway. [PDF]

Oncol Res
Luo L, Guan F, Wang Z, Li B, Ding X, Song L, Sun L.   +6 more
europepmc   +1 more source

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source

Astrocyte heterogeneity in brain metastases

Molecular Oncology, EarlyView.
Astrocytes emerge as pivotal regulators of metastatic colonization, survival, immune remodeling, and therapy response associated with an increasing heterogeneity that requires spatially and longitudinally resolved approaches to uncover regulatory programs and guide context‐specific therapies.
Carolina Hernández‐Oliver, Neibla Priego, Manuel Valiente   +2 more
wiley   +1 more source

Study on the Variation of Resistance Factor of Polymer Microspheres with Distance from the Injection Well

ACS Omega
Jianbing Li, Xingcai Wu, Gang Shi, Liwei Niu   +3 more
doaj   +1 more source

RETRACTION: Silencing CDR1as Enhances the Sensitivity of Breast Cancer Cells to Drug Resistance by Acting as a miR-7 Sponge to Down-Regulate REGγ. [PDF]

J Cell Mol Med
europepmc   +1 more source